about
The serpin PAI-1 inhibits cell migration by blocking integrin alpha V beta 3 binding to vitronectinLow density lipoprotein receptor-related protein-1 (LRP1) regulates thrombospondin-2 (TSP2) enhancement of Notch3 signalingMatrix-bound PAI-1 supports cell blebbing via RhoA/ROCK1 signalingNeuroserpin Differentiates Between Forms of Tissue Type Plasminogen Activator via pH Dependent Deacylation.The active conformation of plasminogen activator inhibitor 1, a target for drugs to control fibrinolysis and cell adhesionMechanistic characterization and crystal structure of a small molecule inactivator bound to plasminogen activator inhibitor-1Familial dementia caused by polymerization of mutant neuroserpinNeuroserpin, a brain-associated inhibitor of tissue plasminogen activator is localized primarily in neurons. Implications for the regulation of motor learning and neuronal survivalDual role for plasminogen activator inhibitor type 1 as soluble and as matricellular regulator of epithelial alveolar cell wound healingPharmacological targeting of the PDGF-CC signaling pathway for blood-brain barrier restoration in neurological disordersIdentification of a novel targeting sequence for regulated secretion in the serine protease inhibitor neuroserpin.The tissue-type plasminogen activator-plasminogen activator inhibitor 1 complex promotes neurovascular injury in brain trauma: evidence from mice and humansPresymptomatic activation of the PDGF-CC pathway accelerates onset of ALS neurodegeneration.Neuroserpin polymorphisms and stroke risk in a biracial population: the stroke prevention in young women studyTissue-type plasminogen activator requires a co-receptor to enhance NMDA receptor function.Characterization of a novel class of polyphenolic inhibitors of plasminogen activator inhibitor-1Visceral adipose tissue inflammation accelerates atherosclerosis in apolipoprotein E-deficient mice.Plasminogen activator-1 overexpression decreases experimental postthrombotic vein wall fibrosis by a non-vitronectin-dependent mechanism.Development of inhibitors of plasminogen activator inhibitor-1.Platelet-derived growth factor (PDGF)-induced tyrosine phosphorylation of the low density lipoprotein receptor-related protein (LRP). Evidence for integrated co-receptor function betwenn LRP and the PDGF.Antimetastatic potential of PAI-1-specific RNA aptamers.Structure-function relationships of plasminogen activator inhibitor-1 and its potential as a therapeutic agent.Plasminogen activator inhibitor-1 inhibits angiogenic signaling by uncoupling vascular endothelial growth factor receptor-2-αVβ3 integrin cross talk.Proteomic analysis of the Vibrio cholerae type II secretome reveals new proteins, including three related serine proteasesVitronectin-binding PAI-1 protects against the development of cardiac fibrosis through interaction with fibroblastsA plasminogen activator inhibitor type 1 mutant retards diabetic nephropathy in db/db mice by protecting podocytesTissue-type plasminogen activator-mediated shedding of astrocytic low-density lipoprotein receptor-related protein increases the permeability of the neurovascular unit.Tissue-type plasminogen activator and neuroserpin: a well-balanced act in the nervous system?Identification of a neurovascular signaling pathway regulating seizures in miceA mechanism for assembly of complexes of vitronectin and plasminogen activator inhibitor-1 from sedimentation velocity analysis.Imatinib treatment reduces brain injury in a murine model of traumatic brain injuryPAI-1 promotes the accumulation of exudate macrophages and worsens pulmonary fibrosis following type II alveolar epithelial cell injury.Structural similarity of the covalent complexes formed between the serpin plasminogen activator inhibitor-1 and the arginine-specific proteinases trypsin, LMW u-PA, HMW u-PA, and t-PA: use of site-specific fluorescent probes of local environmentA CCR2 macrophage endocytic pathway mediates extravascular fibrin clearance in vivo.Rosuvastatin reduced deep vein thrombosis in ApoE gene deleted mice with hyperlipidemia through non-lipid lowering effects.Identification of tissue-type plasminogen activator-specific plasminogen activator inhibitor-1 mutants. Evidence that second sites of interaction contribute to target specificity.Plasminogen activator inhibitor-1 mitigates brain injury in a rat model of infection-sensitized neonatal hypoxia-ischemia.Tissue-type plasminogen activator induces opening of the blood-brain barrier via the LDL receptor-related protein.PAI-1 and functional blockade of SNAI1 in breast cancer cell migration.Therapeutic administration of plasminogen activator inhibitor-1 prevents hypoxic-ischemic brain injury in newborns.
P50
Q24310652-EF69939F-EAAD-4C92-9212-A0A3FCB81606Q24312809-C71D842C-77CB-451D-A4A9-8726621E840CQ27308674-E58B59E5-BBAD-4B65-B40B-703B000764C4Q27319705-3B0C32D2-1E1F-4DFC-9DFB-CB1C8FCE03E0Q27618622-D2DDF329-7405-4BE6-8630-6A32A4C6651DQ27680739-2E1061FE-47F2-4931-807A-B50472440934Q28145741-C7878D75-4D55-4BCA-9DEB-C3CC0A37416EQ28257331-CF9CB5FF-6115-47E4-AD81-8CD2907F9C64Q28580473-FB16CC5F-13ED-428F-AE16-9146ECBE27D9Q29048615-0627E08E-2864-495B-BF1A-55833D689836Q29465533-128A64E4-421F-49A6-9A24-2E97588CA4B9Q30528502-75AE459D-A0A3-4C9C-837C-963D56555168Q30746065-E389015C-1F51-4C4B-B60F-80EB91A5D5FEQ33303923-9ACF33DE-C19D-4E28-A4D4-621C1D7FACDFQ33369942-E7FB833B-A997-4CDD-A3AF-7C2CF7569708Q33522880-49595285-DBAD-4C82-9F8E-49A3DFA7FDF6Q33554780-D24C1C6C-3CEA-476A-8977-E76BFE6C7BA0Q34021916-4D220974-906F-4FDB-BF75-9CA7B8EEA21CQ34073198-C191579F-AF7E-482F-B775-01E13A74E1D4Q34114977-80C5F697-C72B-46E3-9CF0-7D4093E9414BQ34167905-9F42C87D-91DA-4136-A143-4DBF77476581Q34693493-4D98D1C1-FC56-4451-B795-633A57A1EBF5Q34735474-6F1439C7-1525-49BF-927C-488769F7BFD9Q34947350-0101125F-B511-4D03-8227-29CB90B6DF91Q35180538-A7EBFDD9-2B31-4EBE-A075-F6FECD08EBF9Q35185276-0F148840-D324-402B-9C25-87679EE259D5Q35751067-19338546-0EE5-42F4-B29D-B12C80588ED2Q35840293-0EB61CA9-5607-4566-824F-0BF1D00F5A17Q35935089-D19E08DA-D200-4103-8579-31ABADE1BEBAQ36083029-5C8F1B59-6800-4DBB-AB6B-6B26808108EEQ36129940-4856D1BF-24A5-441F-9455-589839A595F3Q36486253-53E93715-C342-4869-852D-3EA54919436DQ36639269-FEED3373-8F0D-4928-ADBE-3CE305B0B593Q36651337-63B0A289-5BD2-40FB-8EA3-8E38CA01B38DQ36674896-7A6529D5-167E-44F5-B1CC-91E67CDF0A53Q36700767-0A7FFD9A-ED1C-4EAD-A283-18CD1AE2613FQ36736945-B366C3D2-6983-4FB3-B414-09E494D10ACEQ36991072-F8DC343C-4EC2-4752-9E6F-5C1CC7FFE208Q37131335-1926C978-7B6F-4D73-9758-83304D2C0EACQ37361862-B398D3FE-798D-4C16-98C4-69AA5C79E22A
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Daniel A Lawrence
@es
Daniel A Lawrence
@nl
Daniel A Lawrence
@sl
Daniel A. Lawrence
@en
type
label
Daniel A Lawrence
@es
Daniel A Lawrence
@nl
Daniel A Lawrence
@sl
Daniel A. Lawrence
@en
prefLabel
Daniel A Lawrence
@es
Daniel A Lawrence
@nl
Daniel A Lawrence
@sl
Daniel A. Lawrence
@en
P106
P1153
7402207276
P21
P2798
P31
P496
0000-0003-3126-1935